DARE BIOSCIENCE, INC.
About DARE BIOSCIENCE, INC.
Daré Bioscience, Inc. is a public biotechnology company focused on developing women's health treatments, including investigational products for HPV-related cervical disease, preterm birth prevention, and contraception. The company leverages non-dilutive grant funding from NIH and NIAID to advance its pipeline of intravaginal ring and other technologies. It trades on NASDAQ under DARE and has secured multiple grants totaling over $43 million for its programmable drug delivery platform.
- 🔗 Dare Bioscience risks Nasdaq delisting over market value By Investing.com
- 🔗 Funding - Daré Bioscience | Leaders in Vaginal Health and Clinical Development in Women's Health
- 🔗 Dare Bioscience granted extension by Nasdaq to regain compliance
- 🔗 Daré Bioscience NIH $2M preterm birth funding extended | DARE Stock News
- 🔗 Daré Bioscience, Inc.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Received multiple NIH grants exceeding $43M in non-dilutive funding for women's health pipeline.
- Initiating Phase 3 trial for Sildenafil and advancing DARE-HPV with NIAID support.
- Granted Nasdaq extension to regain compliance via capital raising and equity improvement plan.
- Reported $4.5M comprehensive loss in FY2024 while reducing G&A expenses by 24%.
Ask StreetZero about DARE BIOSCIENCE, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account